Preclinical evaluation of a CCL19 immune-potentiated DNA cancer vaccine.

Søren Vester Kofoed¹, Marina Barrio-Calvo², Michail Angelos Pavlidis², Daniela Kleine-Kohlbrecher², Mads Lausen², Cherie Lunabjerg-Vestergaard², Nadia Viborg², Christian Garde², Birgitte Rønø², Stine Friis³

¹Evaxion Biotech, Hørsholm, Denmark. svk@evaxion.ai.

²Evaxion Biotech, Hørsholm, Denmark.

³Evaxion Biotech, Hørsholm, Denmark. sf@evaxion.ai.

PubMed PMC DOI PDF

Abstract

Plasmid DNA vectors are emerging as a versatile antigen delivery platform for personalized cancer vaccines. Here, we report a comprehensive preclinical evaluation of a modular DNA cancer vaccine that targets antigen-presenting cells and encodes tumor-specific antigens (TSAs), including neoantigens and endogenous retroviral (ERV) antigens. To specifically direct the TSAs to APCs, the chemokine C-C…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.